Search

Your search keyword '"Haba, Masami"' showing total 13 results
Start Over Author "Haba, Masami" Search Limiters Available in Library Collection
13 results on '"Haba, Masami"'

1. Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene–rearranged acute lymphoblastic leukemia

Author

Takachi, Takayuki, Watanabe, Tomoyuki, Miyamura, Takako, Moriya Saito, Akiko, Deguchi, Takao, Hori, Toshinori, Yamada, Tomomi, Ohmori, Shigeru, Haba, Masami, Aoki, Yuki, Ishimaru, Sae, Sasaki, Shinya, Ohshima, Junjiro, Iguchi, Akihiro, Takahashi, Yoshiyuki, Hyakuna, Nobuyuki, Manabe, Atsushi, Horibe, Keizo, Ishii, Eiichi, Koh, Katsuyoshi, and Tomizawa, Daisuke

Published
2021
Full Text
View/download PDF

2. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial

Author

Tomizawa, Daisuke, primary, Miyamura, Takako, additional, Imamura, Toshihiko, additional, Watanabe, Tomoyuki, additional, Moriya Saito, Akiko, additional, Ogawa, Atsushi, additional, Takahashi, Yoshihiro, additional, Hirayama, Masahiro, additional, Taki, Tomohiko, additional, Deguchi, Takao, additional, Hori, Toshinori, additional, Sanada, Masashi, additional, Ohmori, Shigeru, additional, Haba, Masami, additional, Iguchi, Akihiro, additional, Arakawa, Yuki, additional, Koga, Yuhki, additional, Manabe, Atsushi, additional, Horibe, Keizo, additional, Ishii, Eiichi, additional, and Koh, Katsuyoshi, additional

Published
2020
Full Text
View/download PDF

3. Intensive Chemotherapy Along with Aggressive Supportive Care Can Spare Stem Cell Transplantation in a Subset of Patients without Compromising an Outcome in Infants with Acute Lymphoblastic Leukemia; A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Trial MLL-10

Author

Tomizawa, Daisuke, primary, Miyamura, Takako, additional, Imamura, Toshihiko, additional, Watanabe, Tomoyuki, additional, Saito, Akiko Moriya, additional, Ogawa, Atsushi, additional, Takahashi, Yoshihiro, additional, Hirayama, Masahiro, additional, Arakawa, Yuki, additional, Taki, Tomohiko, additional, Deguchi, Takao, additional, Hori, Toshinori, additional, Omori, Sakae, additional, Haba, Masami, additional, Iguchi, Akihiro, additional, Koga, Yuuki, additional, Manabe, Atsushi, additional, Horibe, Keizo, additional, Ishii, Eiichi, additional, and Koh, Katsuyoshi, additional

Published
2019
Full Text
View/download PDF

4. Hematopoietic stem cell transplantation for infants with high-risk KMT2Agene–rearranged acute lymphoblastic leukemia

Author

Takachi, Takayuki, Watanabe, Tomoyuki, Miyamura, Takako, Moriya Saito, Akiko, Deguchi, Takao, Hori, Toshinori, Yamada, Tomomi, Ohmori, Shigeru, Haba, Masami, Aoki, Yuki, Ishimaru, Sae, Sasaki, Shinya, Ohshima, Junjiro, Iguchi, Akihiro, Takahashi, Yoshiyuki, Hyakuna, Nobuyuki, Manabe, Atsushi, Horibe, Keizo, Ishii, Eiichi, Koh, Katsuyoshi, and Tomizawa, Daisuke

Abstract

The role of allogeneic hematopoietic stem cell transplantation (HSCT) for infants with acute lymphoblastic leukemia (ALL) and KMT2Agene rearrangement (KMT2A-r) is controversial in terms of both its efficacy and potential for acute and late toxicities. In Japanese Pediatric Leukemia/Lymphoma Study Group trial MLL-10, by introducing intensive chemotherapy, indication of HSCT was restricted to patients with high-risk (HR) features only (KMT2A-r and either age <180 days or presence of central nervous system leukemia). Of the 56 HR patients, 49 achieved complete remission. Forty-three patients received HSCT in first remission including 38 patients receiving protocol-specified HSCT with conditioning consisting of individualized targeted doses of busulfan, etoposide, and cyclophosphamide. Three-year event-free survival (EFS) of 56.8% (95% confidence interval [CI], 42.4% to 68.8%) and overall survival of 80.2% (95% CI, 67.1% to 88.5%) were accomplished. Univariable analysis showed that Interfant-HR criteria and flow cytometric minimal residual disease (MRD; ≥0.01%), both at the end of induction and at the end of consolidation (EOC), were significantly associated with poorer EFS. In the multivariable analysis, positive MRD at EOC was solely associated with poor EFS (P< .001). Rapid pretransplant MRD clearance and tailored HSCT strategy in the MLL-10 trial resulted in a favorable outcome for infants with HR KMT2A-r ALL. However, considering the high rate of potentially life-threatening toxicities and the risk of late effects, its indication should be further restricted or even eliminated in the future by introducing more effective therapeutic modalities with minimal toxicities. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as #UMIN000004801.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results